[PRNewswire] Good news to patients with corneal blindness: MIOK
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Keratoprosthesis, the World's First Artificial Cornea of 100% Non-biological Materials has been approved for listing in China.
(BEIJING, Jan. 19, 2022 PRNewswire=연합뉴스) On December 7, 2021, MIOK Keratoprosthesis was approved for listing by NMPA, the Chinese agency for regulating drugs and medical devices. MIOK Keratoprosthesis is the world's first ever approved artificial cornea that requires no co-implantation of donor corneas, and is of great significance across the 60 million patients with corneal blindness worldwide, as MIOK Keratoprosthesis makes it no longer impossible to restore sight to patients with corneal blindness, and ease the burden on their families.
Corneal transplantation is one of the key means to restore sight to patients with corneal blindness. However, there is a high risk for corneal grafting failures and server postoperative complications usually due to the complex immunologic responses to incompatibility in a transplanted organ. Other artificial corneas requiring co-implantation of donor corneas can not avoid such risks either. So MIOK Keratoprosthesis, an artificial cornea of 100% of non-biological materials and requiring no co-implantation of donor corneas, is an ideal option for treating patients with corneal blindness.
MIOK Keratoprosthesis is mainly made of clear PMMA plastic with excellent optical properties and tissue tolerance, and it is intended to restore sight to patients with corneal blindness by providing a transparent optical pathway through an opacified cornea in the treated eye.
With special design and processing, MIOK Keratoprosthesis delivers excellent performance in terms of transparency, light transmission and durability, in addition to high biocompatibility and ease of use for surgical operations, which make it quick integrated with surrounding tissues. With comparison with conventional corneal transplantation and other artificial corneas, MIOK Keratoprosthesis requires no co-implantation of donor cornea, which addresses the lack of donor corneas worldwide and effectively reduces the risk of severe postoperative complications and immune rejection responses. Furthermore, MIOK Keratoprosthesis is indicated to patients with corneal blindness, in cases where a corneal transplantation has failed or runs a high risk for failure, especially to patients with corneal graft failures, corneal scarring/vascularization, chemical/thermal burns, autoimmune diseases (Stevens-Johnson syndrome, pemphigoid, etc.), symblepharon, and severe dry eyes, etc. As a result, it is an effective treatment to patients with corneal blindness caused by a wide range of corneal injuries.
About Microkpro Medical
Beijing Microkpro Medical Instrument Co., Ltd. (Microkpro Medical), founded in 1997, is a company that is focused on artificial vision and committed to restoring vision to the blind through high-tech means. With a long-term unremitting efforts of its excellent R&D team, Microkpro Medical has launched a proprietary artificial cornea: MIOK Keratoprosthesis, and completed its registration NMPA on December 7, 2021. NMPA is the Chinese agency for regulating drugs and medical devices.
And Microkpro Medical has a GMP compliant facility in Daxing Biological Pharmaceutical Industry Base, Beijing, with an annual production capacity of 100,000 Keratoprosthesis in ISO 7/Class 10,000 cleanrooms.
Reference
1. Announcement from National Medical Products Administration(NMPA) of China. https://www.nmpa.gov.cn/directory/web/nmpa/yaowen/ypjgyw/20211207172819157.html (First sentence of the first paragraph, Second sentence)
2. Official weibo of the Australian Embassy in China.
https://weibo.com/1918101143/JdrWO1Vwp (First sentence of the first paragraph)
3. Official website of Massachusetts Eye and Ear Center.
https://masseyeandear.org/medical-professionals/keratoprosthesis (Second paragraph, third sentence)
4. Technical Review Report from Center for Medical Device valuation f NMPA
https://www.cmde.org.cn/directory/web/WS01/images/yMu5pL3HxKSjqENRWjIwMDA4NzijqS5wZGY=.pdf (Third paragraph, fourth paragraph, third sentence)
Source: Microkpro Medical
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 전공의 없는 100일…한치도 나아지지 못한 의정 갈등 | 연합뉴스
- 尹대통령, UAE 대통령과 정상회담…원자력·방산 협력 등 논의 | 연합뉴스
- 野, 22대서 채상병특검 재추진…김여사 의혹까지 특검정국 예고 | 연합뉴스
- 국민연금 부부합산 최고 수령액 월 500만원 육박 | 연합뉴스
- AI칩 선두 엔비디아 7% 급등…나스닥 사상 첫 17,000선 돌파마감(종합) | 연합뉴스
- 은행 신용카드 대출 연체 10년 만에 최고 | 연합뉴스
- '대남전단 식별' 한밤중 재난문자에 경기도민 '화들짝' | 연합뉴스
- 尹대통령, 채상병 기록 경찰 이첩 후 이종섭과 3차례 통화(종합) | 연합뉴스
- "가혹행위에 동의하느냐" 질의에 육군총장 묵묵부답 | 연합뉴스
- 정쟁 소용돌이 속 21대 국회 오늘 종료…'민생국회' 과제 22대로 | 연합뉴스